Baylor Scott & White Health

Running trials

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Enrolling by invitation

  RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

  NCT07605390· Baylor Research Institute· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07154290· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

  NCT06456463· Phase 2· Stemline Therapeutics, Inc.· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Ivy Brain Tumor Center· Source

• Recruiting

  Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  NCT04588922· Phase 1/2· Sellas Life Sciences Group· Source

• Active, not recruiting

  Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  NCT02704858· Phase 1/2· Neonc Technologies, Inc.· Source

• Active, not recruiting

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Functional Assessment in Liver Transplantation

  NCT03228290· University of California, San Francisco· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure3 recruiting
• Obesity3 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver cirrhosis1 recruiting
• Lung cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Withdrawn

  A Study to Investigate Leramistat in Patients With IPF

  NCT05951296· Phase 2· Modern Biosciences Ltd· Source

• Completed

  Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

  NCT05130970· Phase 2· CSL Behring· Source

• Completed

  A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Phase 4· Eli Lilly and Company· Source

• Completed

  Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

  NCT03500328· Johns Hopkins University· Source

• Completed

  Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

  NCT03269994· Phase 3· Memorial Sloan Kettering Cancer Center· Source

• Completed

  LOWER: Lomitapide Observational Worldwide Evaluation Registry

  NCT02135705· Amryt Pharma· Source